Wendy Komocsar, BSMT (ASCP) SI is currently a Research Advisor with the Immunology Platform at Eli Lilly & Company in Indianapolis, IN. As part of the medical team, she leads pediatric development for an asset being studied in both ulcerative colitis and Crohn’s disease. This work includes designing and leading clinical trials, achieving alignment with global regulatory agencies and merging scientific thinking and business needs to deliver strategic decisions supporting drug development. Previously, Wendy led the Immunotoxicology group at both Lilly and Pharmacia, evaluating the potential effects of therapeutic drug candidates on immune function in preclinical species. Wendy is boarded in Immunology and Flow Cytometry.